Susan Prockop, MD
Program Director, Clinical and Translational Research; Outpatient Clinic Director, Hematopoietic Stem Cell Transplant Program; Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Susan Prockop, MD
Program Director, Clinical and Translational Research; Outpatient Clinic Director, Hematopoietic Stem Cell Transplant Program; Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Education
Medical School
Columbia College of Physicians & Surgeons
1993
New York
NY
Residency
Pediatrics
Babies and Children's Hospital, College of Physicians & Surgeons, Columbia University Medical Center
1997
New York
NY
Fellowship
Pediatric Hematology/Oncology
Memorial Sloan Kettering Cancer Center
2003
New York
NY
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
Dr. Susan Prockop is an attending on the pediatric stem cell transplant program. Dr. Prockop trained in Pediatric Hematology Oncology at Memorial Sloan Kettering Cancer Center/Weill Cornell where she joined the faculty in 2004 specializing in the care of children and young adults with life-threatening blood disorders including cancer, myelodysplastic syndromes (MDS), and non-malignant disorders of blood forming and immune cells. Dr Prockop has specific expertise in the care of patients with immune deficiencies and immune dysregulation and is passionate about the importance of working with a multidisciplinary team to address the needs of each patient and their family. She conducts research that aims to improve the outcomes of children undergoing stem cell transplant and to move advances in the field of transplant, gene and cellular therapies to patients in need as rapidly as possible.
Dr. Prockop moved to Dana Farber/Boston Children’s in 2021 as the Program Director for Clinical and Translational Research and the Outpatient Clinic. In Boston she is continuing her work investigating the role of viral specific T cells in the treatment of EBV and CMV infections in patients with defects in their intrinsic immune control of these viruses. In addition, Dr. Prockop works with teams from centers across the United States and Internationally as a collaborative member of committees who share her goals. She is a principal investigator and co-investigator of several multicenter transplant, cellular therapy, and gene therapy clinical trials and is designing treatment regimens with the aim of reducing the side effects of stem cell transplantation by limiting the risk of the post-transplant complications of graft versus host disease and infection and using less toxic chemotherapy.
Publications
Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults. View Abstract
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. View Abstract
The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. View Abstract
Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature. View Abstract
Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. View Abstract
Successful hematopoietic cell transplantation utilizing myeloablative reduced-toxicity conditioning in Chediak-Higashi syndrome. View Abstract
Releasing our model T - chimeric antigen receptor (CAR) T-cells for autoimmune indications. View Abstract
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. View Abstract
The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee. View Abstract
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. View Abstract
Immune milestones to predict CMV after letermovir. View Abstract
International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell-based genomic therapies and the challenges faced. View Abstract
Editorial: Checkpoint inhibition in hematologic malignancies. View Abstract
A Novel Combination of Compound Heterozygous Variants in IFNGR1 Causing Complete IFNGR1 Deficiency. View Abstract
Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients. View Abstract
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. View Abstract
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. View Abstract
Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients. View Abstract
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. View Abstract
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study. View Abstract
Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation. View Abstract
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. View Abstract
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. View Abstract
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. View Abstract
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. View Abstract
Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. View Abstract
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. View Abstract
T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. View Abstract
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. View Abstract
Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis. View Abstract
Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. View Abstract
Case Report: Cytomegalovirus-specific T-lymphocyte infusion for resistant cytomegalovirus retinitis. View Abstract
Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. View Abstract
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. View Abstract
Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. View Abstract
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia. View Abstract
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. View Abstract
International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. View Abstract
Annexin A2 Loss After Cardiopulmonary Bypass and Development of Acute Postoperative Respiratory Dysfunction in Children. View Abstract
Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. View Abstract
The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. View Abstract
T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy. View Abstract
Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation. View Abstract
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy. View Abstract
Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. View Abstract
Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. View Abstract
Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. View Abstract
Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome. View Abstract
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. View Abstract
Towards a standard of care in transplant for WAS. View Abstract
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. View Abstract
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. View Abstract
Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. View Abstract
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with ß-thalassemia: a phase 1 trial. View Abstract
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. View Abstract
Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology. View Abstract
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. View Abstract
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment. View Abstract
Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. View Abstract
CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. View Abstract
Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers. View Abstract
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses. View Abstract
Expanding the toolbox to combat a pandemic. View Abstract
Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. View Abstract
Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center. View Abstract
Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection. View Abstract
Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. View Abstract
Reticular dysgenesis caused by an intronic pathogenic variant in AK2. View Abstract
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. View Abstract
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. View Abstract
Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. View Abstract
Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. View Abstract
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. View Abstract
A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. View Abstract
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. View Abstract
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. View Abstract
Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. View Abstract
The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). View Abstract
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. View Abstract
Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. View Abstract
B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. View Abstract
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine. View Abstract
Reprint of: Virus-Specific T Cells: Broadening Applicability. View Abstract
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. View Abstract
Virus-Specific T Cells: Broadening Applicability. View Abstract
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. View Abstract
Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. View Abstract
Approach to adenovirus infections in the setting of hematopoietic cell transplantation. View Abstract
Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. View Abstract
Is My Child Safe? View Abstract
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. View Abstract
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. View Abstract
Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. View Abstract
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors. View Abstract
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. View Abstract
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. View Abstract
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. View Abstract
Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. View Abstract
T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells. View Abstract
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. View Abstract
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. View Abstract
Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. View Abstract
Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. View Abstract
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. View Abstract
High-dose cyclophosphamide for the treatment of refractory T-cell acute lymphoblastic leukemia in children. View Abstract
Safe mobilization of CD34+ cells in adults with ß-thalassemia and validation of effective globin gene transfer for clinical investigation. View Abstract
Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. View Abstract
Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. View Abstract
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. View Abstract
Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita. View Abstract
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. View Abstract
Paroxysmal nocturnal hemoglobinuria in pediatric patients. View Abstract
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. View Abstract
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. View Abstract
Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. View Abstract
Novel strategies for adoptive therapy following HLA disparate transplants. View Abstract
Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. View Abstract
T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia. View Abstract
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). View Abstract
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. View Abstract
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. View Abstract
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. View Abstract
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. View Abstract
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. View Abstract
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. View Abstract
Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. View Abstract
Regulation of thymus size by competition for stromal niches among early T cell progenitors. View Abstract
Functional assessment of alphaEbeta7/E-cadherin interactions in the steady state postnatal thymus. View Abstract
Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus. View Abstract
Stromal cells provide the matrix for migration of early lymphoid progenitors through the thymic cortex. View Abstract
Mapping precursor movement through the postnatal thymus reveals specific microenvironments supporting defined stages of early lymphoid development. View Abstract
Cell migration and the anatomic control of thymocyte precursor differentiation. View Abstract
A novel fluorescence-based system for assaying and separating live cells according to VDJ recombinase activity. View Abstract